18F-fluorodeoxyglucose--positron Emission Tomography/computed Tomography Aids Staging and Predicts Mortality in Patients with Muscle-invasive Bladder Cancer
Authors
Affiliations
Objective: To investigate the association between extravesical (18)F-fluorodeoxyglucose (FDG) avid lesions on FDG-positron emission tomography/computed tomography (PET/CT) and mortality in patients with muscle-invasive bladder cancer.
Methods: An international, bi-institutional cohort study of 211 patients with muscle-invasive bladder cancer who underwent staging CT and FDG-PET/CT imaging. On the basis of the presence of extravesical FDG-avid lesions suspicious for malignancy on PET/CT images, patients were divided into a PET/CT-positive and PET/CT-negative group. Data on staging and mortality were retrospectively analyzed from prospective databases. Kaplan-Meier analyses were performed to compare overall (OS) and disease-specific survival (DSS) between the groups. Multivariable Cox regression models were used to investigate the association between extravesical PET/CT lesions and mortality. Extravesical lesions suspicious for malignancy on conventional CT were included in the models.
Results: Of the 211 patients, 98 (46.4%) had 1 or more extravesical lesions on PET/CT, 113 (53.5%) had a negative PET/CT. Conventional CT revealed extravesical lesions in 51 patients (24.4%). Median follow-up was 18 months. Patients with a positive PET/CT had a significantly shorter OS and DSS (median OS: 14 vs 50 months, P = .001; DSS: 16 vs 50 months, P <.001). In multivariable analysis, the presence of extravesical lesions on PET/CT was an independent prognostic indicator of mortality (OS: hazard ratio = 3.0, confidence interval 95% 1.7-5.1). This association was not statistically significant for conventional CT (hazard ratio = 1.6 (95% confidence interval 0.9-2.7).
Conclusion: On the basis of our results, the presence of extravesical FDG-avid lesions on PET/CT might be considered an independent indicator of mortality.
Gulbahar Ates S, Demirel B, Basar H, Ucmak G Mol Imaging Radionucl Ther. 2024; 33(1):11-18.
PMID: 38390706 PMC: 10899737. DOI: 10.4274/mirt.galenos.2023.65002.
Ozturk H, Karapolat I World J Clin Cases. 2024; 11(36):8447-8457.
PMID: 38188218 PMC: 10768499. DOI: 10.12998/wjcc.v11.i36.8447.
Nishioka E, Tsurusaki M, Kozuki R, Im S, Kono A, Kitajima K Diagnostics (Basel). 2022; 12(11).
PMID: 36428949 PMC: 9689116. DOI: 10.3390/diagnostics12112889.
Role of PET/CT in muscle-invasive bladder cancer.
Kim S Transl Androl Urol. 2021; 9(6):2908-2919.
PMID: 33457264 PMC: 7807314. DOI: 10.21037/tau.2020.03.31.
The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.
Girard A, Vila Reyes H, Shaish H, Grellier J, Dercle L, Salaun P Front Oncol. 2020; 10:565086.
PMID: 33117695 PMC: 7574640. DOI: 10.3389/fonc.2020.565086.